Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma.

about

Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma.

Item

http://www.wikidata.org/entity/Q55315572

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Therapeutic potential of CPI-6 ...... tophagy in clear cell sarcoma.

@en

Therapeutic potential of CPI-6 ...... tophagy in clear cell sarcoma.

@nl

type

Item

label

Therapeutic potential of CPI-6 ...... tophagy in clear cell sarcoma.

@en

Therapeutic potential of CPI-6 ...... tophagy in clear cell sarcoma.

@nl

prefLabel

Therapeutic potential of CPI-6 ...... tophagy in clear cell sarcoma.

@en

Therapeutic potential of CPI-6 ...... tophagy in clear cell sarcoma.

@nl

P1476

Therapeutic potential of CPI-6 ...... utophagy in clear cell sarcoma

@en

P2093

Chiemi Saigo

http://www.w3.org/2001/XMLSchema#string

Toshiaki Moriki

http://www.w3.org/2001/XMLSchema#string

Yusuke Kito

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of T-cadherin (CDH13, H-Cadherin) in human brain and its characteristics as a negative growth regulator of epidermal growth factor in neuroblastoma cells

EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts

Clinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft parts

A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process

Role of autophagy in cancer

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.

The role for autophagy in cancer.

High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases

Metabolic catastrophe as a means to cancer cell death.

P304

e0198940

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0198940

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yuki Egawa

Tamotsu Takeuchi

P577

2018-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29879220

http://www.w3.org/2001/XMLSchema#string

P932

5991736

http://www.w3.org/2001/XMLSchema#string